Company Filing History:
4 out of 263 
4 out of 987 
2 out of 167 Years Active: 2018-2023
Title: Brian Slafer: Innovator in CDK Inhibitors
Introduction
Brian Slafer is a notable inventor based in Lemont, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDKs). With a total of 4 patents to his name, Slafer's work has the potential to impact various therapeutic areas.
Latest Patents
One of Brian Slafer's latest patents involves pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors. These compounds are designed to inhibit various CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patent outlines pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischemia, renal diseases, and cardiovascular disorders. The treatment may also include simultaneous or sequential administration of additional active agents, enhancing its therapeutic efficacy.
Career Highlights
Throughout his career, Brian Slafer has worked with esteemed organizations, including Cancer Research Technology Limited and Emory University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Brian Slafer's notable coworkers include Alexander Bondke and Sebastian Kroll. Their collaborative efforts have further advanced the research and development of innovative therapeutic solutions.
Conclusion
Brian Slafer's contributions to the field of CDK inhibitors exemplify the impact of innovative thinking in pharmaceuticals. His work continues to pave the way for new treatments that address critical health challenges.